PM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Philip Morris International is a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. My direct view is BUY. The stock has a bullish moving-average structure, supportive regulatory/news catalysts around ZYN, positive congressional buying, and several analysts maintaining Buy/Overweight ratings with higher targets. While the MACD is still slightly negative and the stock is extended near resistance, the broader setup is constructive enough to justify buying now rather than waiting.
PM is in an overall bullish trend: SMA_5 > SMA_20 > SMA_200, which signals upward price structure across short-, medium-, and long-term horizons. RSI_6 at 57.8 is neutral-to-mildly bullish, so the stock is not overbought. MACD histogram is slightly negative at -0.0217 but is contracting, which suggests downside momentum is fading. Price at 183.46 is just above pivot 179.18 and below resistance 184.42, with next resistance at 187.65. This indicates the stock is close to an upside breakout area, though not deeply discounted.
The biggest catalyst is the FDA authorization for 20 ZYN nicotine pouch variants with reduced-risk claims, which strengthens Philip Morris's smoke-free strategy and supports future revenue growth. News flow also highlights expanding adoption of smoke-free products and management confidence in the category. Congress trading data is positive, with 2 purchase transactions and 0 sales over the last 90 days, suggesting informed buying interest. Analyst sentiment remains supportive overall, with multiple firms raising targets and keeping Buy/Overweight ratings. SwingMax also remains supportive, with an entry signal on 2026-06-05 and the stock up since then.
UBS is only Neutral and recently raised its target to $182, which is now below the current price, showing limited upside from that specific view. Hedge funds and insiders are neutral, so there is no strong buy signal from ownership trends.
No usable quarterly financial snapshot was provided, so I cannot assess the latest quarter's revenue or earnings growth directly. The news summary, however, indicates that smoke-free products are becoming a larger share of net revenues, with PMI estimating these products could represent 43% of Q1 2026 net revenues and over 43 million legal-age consumers using its smoke-free products by end-2025. That points to ongoing growth in the newer product mix, especially in the latest reported season referenced by the news flow.
Recent analyst trend is still constructive despite some target trimming. Morgan Stanley raised its target to $200 and stays Overweight. BofA raised its target to $209 and stays Buy, citing FDA policy changes and smoke-free growth. Stifel also remains Buy with a $195 target. UBS is the main cautious view, lifting its target to $182 but keeping Neutral. Overall Wall Street pros are more positive than negative, with the bullish case centered on ZYN, smoke-free expansion, and durable earnings, while the cautious case is valuation and only moderate near-term upside from the current price.
